Request to Join
has invited you to join this group
Dr. Roy S. Herbst is Ensign Professor of Medicine, Professor of Pharmacology, Chief of Medical Oncology, Director of the Thoracic Oncology Research Program, and Associate Director for Translational Research at Yale Comprehensive Cancer Center and Yale School of Medicine in New Haven, CT. Dr. Herbst has led the Phase I development of several of the new generation of targeted agents for NSCLC, including gefitinib, erlotinib, cetuximab, and bevacizumab. He is co-lead for the BATTLE-1 effort, co-leads the subsequent BATTLE-2 clinical trial program, and serves as a Co-Program Leader of the Developmental Therapeutics Program for the YCC Cancer Center Support Grant (CCSG). He is a member of the National Cancer Policy Forum for which he has organized an IOM meeting focused on policy issues in personalized medicine. His laboratory work is focused on angiogenesis and dual EGFR/VEGFR inhibition in NSCLC. Dr. Herbst is author or co-author of more than 250 publications, including peer-reviewed journal articles, abstracts, and book chapters. He has contributed his work to many prominent journals, such as Journal of Clinical Oncology, Clinical Cancer Research, Lancet, and the New England Journal of Medicine. Dr. Herbst is an active member of ASCO, AACR, IASLC (International Association for the Study of Lung Cancer), RTOG (Radiation Therapy Oncology Group), and SWOG (Southwest Oncology Group Lung Committee).